Solara Active Pharma
Solara Active Pharma Sciences is a publicly listed Indian pure-play Active Pharmaceutical Ingredient manufacturer operating six manufacturing facilities and serving global pharmaceutical companies across 75+ countries with 60+ commercial APIs and CRAMS services.
- Company typePublic
- Founded2017
- HeadquartersChennai, India
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Solara Active Pharma does
Solara Active Pharma Sciences Limited is a publicly listed Indian pure-play Active Pharmaceutical Ingredient (API) manufacturer, incorporated in 2017 through a composite demerger from Strides Shasun Limited and SeQuent Scientific Limited, with shares listed on BSE (541540) and NSE (SOLARA) since June 27, 2018. The company operates six manufacturing facilities across India (Ambernath, Cuddalore, Mangaluru, Pondicherry, Mysore, Vizag) supported by one R&D center with a team of 150+ chemists, and serves global pharmaceutical manufacturers in 75+ countries through sales offices in India, USA, Japan, and South Korea. Its product portfolio spans 60+ commercial APIs across therapeutic categories including NSAIDs, cardiovascular agents, anticonvulsants, immunosuppressants, anti-retrovirals, and phosphate binders, with a pipeline of 10 additional APIs in development.
The company's competitive position is anchored in regulatory compliance, with 33 successful USFDA audits across its sites and approvals from EDQM, PMDA, WHO, KFDA, TGA, MHRA, EU-GMP, ANVISA, Cofepris, and Health Canada, enabling 75% of revenue to come from regulated markets. Technical capabilities include flow chemistry, chiral chemistry, high-potency API (HPAPI) manufacturing, multi-temperature reactors (-90°C to +250°C), commercial-scale lyophilization at Vizag, and spray drying and hydrogenation at Cuddalore. Beyond pure API manufacturing, Solara offers Contract Research and Manufacturing Services (CRAMS) spanning early discovery through commercialization for innovator and specialty pharmaceutical companies.
Solara generates revenue primarily through B2B quote-based API sales to global generic pharmaceutical companies, with customized pricing determined by product type, volume, regulatory filings, and delivery specifications. Additional revenue comes from CRAMS engagements billed on a professional services basis. The company employs over 2,500 people and reported FY26 revenue of Rs. 1,368.98 crore (+6.64% YoY) with Q4 FY26 revenue of Rs. 387.29 crore (+41.86% YoY) and Q4 base business EBITDA margin of approximately 26%. The balance sheet has been actively deleveraged through a Rs. 445 crore rights issue completed in May 2024, reducing total debt from Rs. 999 crore to Rs. 500-530 crore and supporting a Crisil rating upgrade to BBB+/Stable. The company is currently evaluating strategic options for its loss-making Ibuprofen API business and closed its Brazilian subsidiary in March 2026 to refocus on core regulated markets.
Solara Active Pharma firmographics
Firmographics- Name
- Solara Active Pharma
- Legal name
- Solara Active Pharma Sciences Limited
- Website
- https://solara.co.in
- Company type
- Public
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Solara Active Pharma Sciences is a publicly listed Indian pure-play Active Pharmaceutical Ingredient manufacturer operating six manufacturing facilities and serving global pharmaceutical companies across 75+ countries with 60+ commercial APIs and CRAMS services.
- Ownership category
- akta.pro rank
Solara Active Pharma industry classification
Industry- Product category
- Active Pharmaceutical Ingredients (APIs)
- NAICS
- Pharmaceutical and Medicine Manufacturing (32541), Scientific Research and Development Services (5417)
- SIC
- Medicinal Chemicals & Botanical Products (2833), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Generic APIs & Intermediates (Active Ingredients) (HLAIABAG)
- akta.pro secondary industries
- Small-Molecule API Commercial Manufacturing (HLAGAHAB), GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL)
Keywords
Where Solara Active Pharma is headquartered
LocationHeadquarters
- HQ city
- Chennai
- HQ country
- India
- HQ region
- Asia
Offices12 records
Markets served
Solara Active Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Personnel, Technology or R&D, Infrastructure, Marketing or Sales
Revenue model
- API Manufacturing and Sales: Manufacturing and sale of Active Pharmaceutical Ingredients (APIs) to global pharmaceutical companies. Revenue from sale of 60+ commercial APIs across multiple therapeutic categories including NSAIDs, cardiovascular agents, anticonvulsants, and others.
- CRAMS (Contract Research and Manufacturing Services): Contract research and manufacturing services spanning the entire drug development lifecycle from early discovery through commercialization, including analytical services, impurity synthesis, and regulatory support.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | B2B API sales with customized pricing |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels4 records
Solara Active Pharma product offering
Product offeringCore offering
Solara Active Pharma Sciences manufactures and supplies over 60 commercial Active Pharmaceutical Ingredients (APIs) across therapeutic categories including NSAIDs, cardiovascular agents, anticonvulsants, immunosuppressants, anti-retrovirals, and phosphate binders, alongside Contract Research and Manufacturing Services (CRAMS) that span the full drug development lifecycle from discovery through commercial supply. The company produces APIs at six Indian manufacturing facilities and two R&D centres, serving pharmaceutical customers in 75+ countries with 75% of revenue from regulated markets.
Product overview
Solara Active Pharma Sciences is a pure-play Active Pharmaceutical Ingredient (API) manufacturer with three decades of experience. The company operates through three core pillars: API manufacturing (offering over 60 commercial APIs across therapeutic categories), Research and Development (supporting new product development and process optimization with capabilities in flow chemistry, chiral chemistry, and high-potency APIs), and CRAMS (Contract Research and Manufacturing Services covering the full drug development chain from discovery through commercialization). The product portfolio centers on complex, high-value APIs including multiple Ibuprofen variants, specialty products like Sevelamer, Sugammadex, and Lanthanum Carbonate, along with APIs for cardiovascular, neurological, anti-infective, and anti-parasitic applications. The company serves customers in over 75 countries and is pursuing a vision to be among the Top 10 pure-play global API companies.
Differentiator
Problem solved
Functional benefit
Products and services
- Active Pharmaceutical Ingredients (APIs) Portfolio Pure-play API manufacturing offering over 60 commercial APIs across therapeutic categories including NSAIDs, cardiovascular agents, antifungals, antibiotics, anticonvulsants, immunosuppressants, anti-retrovirals, and phosphate binders for sale to global pharmaceutical manufacturers.
- CRAMS (Contract Research and Manufacturing Services) Contract research and manufacturing services spanning the entire drug development chain from hit-to-lead and lead optimization through preclinical synthesis, cGMP production for Phase 1-3 trials, process validation, and commercial manufacturing, including analytical services, impurity synthesis, and regulatory filing support for innovative pharmaceutical customers.
- Research and Development Services Internal R&D services supporting API development with expertise in flow chemistry, chiral chemistry, polymer chemistry, sugar chemistry, inorganic chemistry, photochemistry, high-potency APIs, and enzymatic chemistry, operating across 7 synthesis labs with 60 fume hoods, a dedicated HPAPI lab, flow chemistry lab, process safety lab, and process engineering lab staffed by 130+ scientists.
- Sevelamer Carbonate API Phosphate binder Active Pharmaceutical Ingredient used for the treatment of hyperphosphatemia, manufactured at the Cuddalore, Tamil Nadu facility and supplied to pharmaceutical customers.
- Sugammadex API API used for reversal of neuromuscular blocking agents, supported by USDMF and EDMF regulatory filings, and produced at Solara's parenteral manufacturing facility.
- Lanthanum Carbonate Tetrahydrate API Active Pharmaceutical Ingredient indicated for the treatment of hyperphosphatemia, supported by USDMF and Japan regulatory filings.
- Levetiracetam API Anticonvulsant Active Pharmaceutical Ingredient manufactured at Solara's Cuddalore and Ambernath facilities for neurological indications.
- Gabapentin API Active Pharmaceutical Ingredient with USDMF, CEP, Canada, and Korea regulatory filings, used for neurological applications and supplied to global pharmaceutical customers.
- Dolutegravir API Anti-retroviral Active Pharmaceutical Ingredient with WHO regulatory filing for HIV treatment.
- Edaravone API Active Pharmaceutical Ingredient for amyotrophic lateral sclerosis (ALS) treatment, available in oral liquid and parenteral dosage forms.
- Albendazole API Anthelmintic Active Pharmaceutical Ingredient used for anti-parasitic treatment.
- Praziquantel API Anthelmintic Active Pharmaceutical Ingredient with USDMF, WHO, and Canada regulatory filings for anti-parasitic treatment.
- Flucytosine API Antimycotic Active Pharmaceutical Ingredient with USDMF and WHO filings, supplied in oral solid, parenteral, and vaginal dosage forms.
- Cinacalcet Hydrochloride API Calcimimetic agent Active Pharmaceutical Ingredient manufactured at the Pondicherry facility with USDMF and Korea regulatory filings.
- Sevelamer HCl API Hypophosphatemic agent Active Pharmaceutical Ingredient available in oral liquid and oral solid dosage forms for the treatment of hyperphosphatemia.
- Ibuprofen API Product Line Major Ibuprofen API product line producing multiple grade variants and salt forms—including standard grades (S250, S380, S500, SHD, SN) and specialized forms (Arginine, Lysine, Sodium, Sodium dihydrate, DC66, DC85, DC90)—for sale to pharmaceutical manufacturers globally, with the company evaluating strategic options for this segment.
Quantifiable outcome
- Q4 FY26 revenue of Rs. 387.29 crore, up 41.86% YoY
- +3 more outcomes
Companies that use Solara Active Pharma
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles3 records
Solara Active Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Solara Active Pharma partnerships and signals
Strategic signalScale indicators10 records
Recent moves9 records
Expansion highlights5 records
Solara Active Pharma competitors and assessment
Company assessmentDirect peers
- Aurobindo Pharma: Large Indian-headquartered manufacturer of APIs and finished dosage formulations with significant regulated-market exposure (USFDA, EDQM). Directly comparable to Solara as a vertically integrated Indian API producer serving global generic and branded pharma customers.
- Divi's Laboratories: Pure-play Indian API and intermediate manufacturer with a focus on complex chemistry, custom synthesis, and nutraceutical ingredients. Closest direct peer to Solara given pure-play API focus, complex chemistry capabilities (including peptides), and strong regulated market exposure.
- Laurus Labs: Indian API manufacturer with substantial CRAMS/CDMO operations, including capabilities in complex chemistry and HPAPI handling. Directly comparable to Solara's pure-play API plus CRAMS combination with overlap in customer base and geographic markets.
- Neuland Laboratories: India-based pure-play API and CRAMS manufacturer serving global generic and innovator pharma customers. Closely comparable to Solara's product mix, regulatory footprint (USFDA, EDQM approvals), and complex chemistry capabilities.
- Jubilant Pharmova: Indian-headquartered pharma company with significant API manufacturing plus CRAMS (through Jubilant Biosys) businesses. Comparable to Solara's diversified API and contract services model with overlap in regulated market approvals and complex chemistry offerings.
- Ipca Laboratories: Indian API and formulation manufacturer with strong presence in therapeutic categories including anti-malarials and NSAIDs that overlap with Solara's portfolio. Comparable scale and regulated-market footprint with similar USFDA inspection history.
- Granules India: Indian pharmaceutical company with significant API operations alongside finished formulations. Comparable to Solara in API product breadth, regulatory approvals across major markets, and customer mix of global generic pharma manufacturers.
- MSN Laboratories: India-based API and formulation manufacturer with strong complex generics and API presence. Comparable to Solara's product diversification across therapeutic categories and investment in complex chemistry capabilities.
Regional players
- Sequent Scientific: Indian-headquartered animal health API manufacturer from which Solara's human API business was originally demerged in 2017. Highly relevant historical peer given shared operating DNA, though now focused on veterinary rather than human APIs.
Emerging players
- Sequens (SEQENS Group): European-headquartered global API and CDMO with complex chemistry capabilities spanning small molecules, specialty APIs, and contract development. Comparable to Solara on CRAMS business model and complex API manufacturing footprint, serving similar global generic and innovator customers.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Solara Active Pharma social profiles
Digital presenceSolara Active Pharma compliance and trust
Trust signalCompliance13 records
Solara Active Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Solara Active Pharma leadership team
Management profileNumber of profiles
Profiles12 records
Solara Active Pharma subsidiaries and ownership
Company hierarchySubsidiaries4 records
Solara Active Pharma funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Solara Active Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Solara Active Pharma
What does Solara Active Pharma do?
Solara Active Pharma Sciences manufactures and supplies over 60 commercial Active Pharmaceutical Ingredients (APIs) across therapeutic categories including NSAIDs, cardiovascular agents, anticonvulsants, immunosuppressants, anti-retrovirals, and phosphate binders, alongside Contract Research and Manufacturing Services (CRAMS) that span the full drug development lifecycle from discovery through commercial supply. The company produces APIs at six Indian manufacturing facilities and two R&D centres, serving pharmaceutical customers in 75+ countries with 75% of revenue from regulated markets.
Is Solara Active Pharma a public or private company?
Solara Active Pharma is a public company. It is classified as public and is currently operating.
When was Solara Active Pharma founded?
Solara Active Pharma was founded in 2017. It employs 1,001 to 5,000 people.
Where is Solara Active Pharma based?
Solara Active Pharma is headquartered in Chennai, India, in the Asia region.
How does Solara Active Pharma make money?
Two revenue lines are on record. API Manufacturing and Sales are the primary driver. The others are CRAMS (Contract Research and Manufacturing Services).
Who are Solara Active Pharma's main competitors?
Direct peers on record are Aurobindo Pharma, Divi's Laboratories, Laurus Labs, Neuland Laboratories, Jubilant Pharmova, Ipca Laboratories, Granules India and MSN Laboratories. Sequent Scientific is listed as a regional player. Sequens (SEQENS Group) is listed as an emerging player.
Does Solara Active Pharma have an API?
No public API is recorded for Solara Active Pharma.
What industry is Solara Active Pharma in?
Solara Active Pharma's product category is Active Pharmaceutical Ingredients (APIs). Its primary akta.pro industry code is HLAIABAG, Generic APIs & Intermediates (Active Ingredients), with a secondary code of HLAGAHAB, Small-Molecule API Commercial Manufacturing. Its NAICS code is 32541 and its SIC code is 2833.